Latest News
Flamel Technologies has invented
two innovative
polymer-based technologies:
• Micropump® for the delivery of small molecule drugs,
including pediatric and geriatric uses.
• Medusa® for the delivery of native protein drugs.
Flamel provides tailored solutions to the industry for
optimized controlled-released delivery of drugs.
• The Company turns already-marketed or new drugs into
more effective and safer medicines.
• Well advanced and rich products pipeline: Genvir™,
Metformin XL, FT-105, IFN alpha-2b XL, IL-2, hGH and EPO.
Research and Development Team
The Company has assembled a strong team of researchers expert in polymer science and biochemistry, including more than 35 Ph.D.s.Flamel is helped in its innovative research and development work by two world renown scientists: Jean-Marie Lehn (Nobel Laureate in Chemistry in 1987) and Professor Christian Trepo, a world renowned expert in liver diseases.
Manufacturing Facility
The Company owns a 103,900-square foot pharmaceutical production facility located in Pessac, France.The Pessac facility and its operation are approved by the European drug agencies and are in substantial compliance with "Good Manufacturing Practice" ("cGMP"). The facility provides Flamel with the capability to manufacture its cGMP-grade pharmaceutical drugs for clinical trials utilizing its Micropump® or Medusa® technologies.